Drug intelligence / Profile preview

autologous neobladder construct

Development stage: Preclinical
Lead developer: Tengion
Administration: Surgical Implantation

Overview

Autologous neobladder construct is a biological/device product developed by Tengion. It is designed for augmentation cystoplasty to treat conditions such as non-neurogenic overactive bladder with urge predominant incontinence and neurogenic bladder secondary to spinal cord injury. The construct aims to increase functional bladder capacity, reduce micturition episodes, and decrease maximum detrusor pressure.

Brand names: Neo-Bladder
Other names: Autologous neo bladder construct

Beyond the preview

Go deeper on autologous neobladder construct.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous neobladder construct.

Explore the full profile